FDA approves atogepant for adults with chronic migraine

The U.S. Food and Drug Administration (FDA) has approved expanding the indication of atogepant (Qulipta) for the preventive treatment of migraine in adults, according to a press release. This is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine. Atogepant has...